Sökning: onr:"swepub:oai:DiVA.org:umu-51470" >
Activating ALK muta...
Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684
-
- Schönherr, Christina (författare)
- Umeå universitet,Institutionen för molekylärbiologi (Medicinska fakulteten)
-
- Ruuth, Kristina (författare)
- Umeå universitet,Institutionen för molekylärbiologi (Medicinska fakulteten)
-
- Yamazaki, Yasuo (författare)
- Umeå universitet,Institutionen för molekylärbiologi (Medicinska fakulteten)
-
visa fler...
-
- Eriksson, Therese (författare)
- Umeå universitet,Institutionen för molekylärbiologi (Medicinska fakulteten)
-
- Christensen, James (författare)
- Pfizer Global Research and Development, Department of Research Pharmacology, La Jolla Laboratories, La Jolla, CA 92121, U.S.A.
-
- Palmer, Ruth H (författare)
- Umeå universitet,Institutionen för molekylärbiologi (Medicinska fakulteten)
-
- Hallberg, Bengt (författare)
- Umeå universitet,Institutionen för molekylärbiologi (Medicinska fakulteten)
-
visa färre...
-
(creator_code:org_t)
- 2011
- 2011
- Engelska.
-
Ingår i: Biochemical Journal. - 0264-6021 .- 1470-8728. ; 440, s. 405-413
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Mutations in the kinase domain of ALK (anaplastic lymphoma kinase) have recently been shown to be important for the progression of the childhood tumour neuroblastoma. In the present study we investigate six of the putative reported constitutively active ALK mutations, in positions G1128A, I1171N, F1174L, R1192P, F1245C and R1275Q. Our analyses were performed in cell-culture-based systems with both mouse and human ALK mutant variants and subsequently in a Drosophila melanogaster model system. Our investigation addressed the transforming potential of the putative gain-of-function ALK mutations as well as their signalling potential and the ability of two ATP-competitive inhibitors, Crizotinib (PF-02341066) and NVP-TAE684, to abrogate the activity of ALK. The results of the present study indicate that all mutations tested are of an activating nature and thus are implicated in tumour initiation or progression of neuroblastoma. Importantly for neuroblastoma patients, all ALK mutations used in the present study can be blocked by the inhibitors, although some mutants exhibited higher levels of drug sensitivity than others.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Cell- och molekylärbiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Cell and Molecular Biology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinsk bioteknologi -- Medicinsk bioteknologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Medical Biotechnology -- Medical Biotechnology (hsv//eng)
Nyckelord
- anaplastic lymphoma kinase (ALK)
- cancer
- Crizotinib
- gain-of-function mutation
- neuroblastoma
- NVP-TAE684
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas